Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Cancer Drugs Fund

- PMLiVE

Merck receives FDA approval for Keytruda combination in gastric cancer

An estimated 26,500 people in the US will be diagnosed with gastric cancer in 2023

- PMLiVE

Merck’s Keytruda combination receives CHMP recommendation for biliary tract cancer

Approximately 211,000 people are diagnosed with the disease globally each year

- PMLiVE

NICE recommends Chiesi’s alpha-mannosidosis enzyme replacement therapy

Alpha-mannosidosis, an extremely rare inherited condition characterised by a broad range of impairments, affects approximately 25 people in England

- PMLiVE

NICE announces launch of refreshed support service for life sciences industry

NICE Advice will support pharmaceutical and healthtech companies and provide patients with access to quality treatments and care

- PMLiVE

Merck shares positive results for adjuvant Keytruda in phase 3 kidney cancer trial

Renal cell carcinoma accounts for approximately 90% of all kidney cancer diagnoses

- PMLiVE

Merck’s Keytruda combination granted FDA approval for biliary tract cancer

Approximately 20,000 people are diagnosed with the disease each year in the US

- PMLiVE

AbbVie’s Parkinson’s disease therapy recommended by NICE for advanced disease

Around 900 adults with advanced Parkinson’s are set to benefit from Produodopa

- PMLiVE

UCL study finds use of existing drugs improves cervical cancer outcomes

The approach was shown to reduce the risk of death or cancer recurrence by 35%

- PMLiVE

Merck shares positive results for Keytruda in early-stage breast cancer

Approximately 298,000 people will be diagnosed with breast cancer in the US this year

- PMLiVE

Merck’s Keytruda granted FDA approval for expanded use in lung cancer

The approval marks the sixth non-small cell lung cancer indication for the anti-PD-1 therapy

- PMLiVE

Merck shares positive results for Keytruda in phase 3 bladder cancer study

Over 82,000 people in the US will be be diagnosed with bladder cancer in 2023

- PMLiVE

Further data for AstraZeneca/Daichii Sankyo’s Enhertu requested by NICE

Enhertu is currently approved for HER2-low metastatic breast cancer in over 30 countries

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links